AbbVie is also advancing its collaborations with other companies. With REGENXBIO, AbbVie is developing a gene therapy for two major eye diseases, with pivotal trial results expected in 2026.

AbbVie's growth prospects remain strong despite the impending decline in revenue from Humira. Click here to read more on why I rate ABBV stock as a Buy.

More Challenges Await AbbVie Following A Disappointing Quarter. Jul. 14, 2023 4:54 PM ET AbbVie Inc. ... So, except for Q1 2023, the company's R&D spending averaged $1.65 billion, ...

IGI Therapeutics SA, a wholly-owned subsidiary of Ichnos Glenmark Innovation (IGI)—an alliance between Glenmark Pharma and Ichnos Sciences Inc.—has signed an exclusive licensing agreement with AbbVie ...

AbbVie ends a six-day losing streak with a 0.88% gain, though concerns over increased R&D costs and earnings revisions continue to weigh on investor sentiment.

AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. The collaboration ...

AbbVie, known for its strong presence in immunology and oncology, has demonstrated resilience in the face of Humira’s patent expiration. The company reported robust financial results in the fourth ...

AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing the impact of $82 million in milestones, and research and development expenses related to acquisitions. The drugmaker ...

AbbVie Ventures knows that challenge intimately, and leverages AbbVie’s in-house expertise as well as its network of third parties to help biotechs work through any hurdles they face.